Levels of Factor VIIc Associated with Decreased Tissue Factor Pathway Inhibitor and Increased Plasminogen Activator Inhibitor-1 in Dyslipidemias

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 16, Issue 1, 1996, Pages 77-81

  Zitoun, Danièle ^a   Bara, Lucienne ^a,b   Basdevant, Arnaud ^b   Samama, Meyer Michel ^a  

^a HÔTEL DIEU   (France)

^b SORBONNE UNIVERSITÉ   (France)

Author keywords

Factor VIIa; Hyperlipidemia; Plasminogen activator inhibitor type 1; Tissue factor pathway inhibitor; Tissue type plasminogen activator

Indexed keywords

BLOOD CLOTTING FACTOR 7A; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; PLASMINOGEN ACTIVATOR; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; ARTICLE; BLOOD CLOTTING; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE PREDISPOSITION; DYSLIPIDEMIA; FEMALE; HUMAN; HYPERLIPIDEMIA; HYPOTHESIS; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; STATISTICAL ANALYSIS; THROMBOGENESIS; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; ANTIGENS; APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; BLOOD GLUCOSE; BODY MASS INDEX; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; FACTOR VII; FACTOR VIIA; FEMALE; HUMANS; HYPERLIPIDEMIAS; LIPOPROTEINS; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; SERINE PROTEINASE INHIBITORS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0030047125     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.16.1.77     Document Type: Article

References (37)

1. Meade TW, Brozovic M, Chakrabart RR, Haines AP, Imeson JD, Mellows S, Miller GJ, North WRS, Stirling Y, Thompson SG. Haemostatic function and ischemic heart disease: principal results of the Northwick Park Heart Study. Lancet. 1986;2:533-537.
2. Dalaker K, Hjermann I, Prydz H. A novel form of factor VII in plasma from men at risk for cardiovascular disease. Br J Haematol. 1985;61:315-322.
3. Miller GJ, Martin JC, Webster J, Wilkes H, Miller NE, Wilkinson WH, Meade TW. Association between dietary fat intake and plasma factor VII coagulant activity: a predictor of cardiovascular mortality. Atherosclerosis. 1986;60:269-277.
4. Constantino M, Merskey C, Kudzma DJ, Zucker MB. Increased activity of vitamin K-dependent clotting factors in human hyperlipoproteinaemia: association with cholesterol and triglyceride levels. Thromb Haemost. 1977;38:465-474.
5. Mitropoulos KA, Miller GJ, Reeves BEA, Wilkes HC, Cruickshank JK. Factor VII coagulant activity is strongly associated with the plasma concentration of large lipoprotein particles in middle-aged men. Atherosclerosis. 1989;76:203-208.
6. De Sousa JC, Soria C, Ayrault-Jarrier M, Pastier D, Bruckert E, Amiral J, Bereziat G, Caen JP. Association between coagulation factors VII and X with triglyceride rich lipoproteins. J Clin Pathol. 1988;41:940-944.
7. Nemerson Y. Tissue factor and haemostasis. Blood. 1988;71:1-8.
8. Wilcox JN, Smith KM, Schwartz SM, Gordon D. Localization of tissue factor in normal vessel and in the atherosclerotic plaque. Proc Natl Acad Sci USA, 1989;86:2839-2843.
9. Novotny WF, Girard TJ, Miletich JP, Broze GJ Jr. Purification and characterization of the lipoprotein-associated coagulation inhibitor from human plasma. J Biol Chem. 1989;264:18832-18837.
10. Sandset PM, Abildgaard U, Pettersen M. A sensitive assay of extrinsic pathway inhibitor (EPI) in plasma and plasma fractions. Thromb Res. 1987;47:389-400.
11. Sandset PM, Sirnes PA, Abildgaard U. Factor VII and extrinsic pathway inhibitor in acute coronary disease Br J Haematol. 1989;72:391-396.
12. Lesnik P, Vonica A, Guerin M, Moreau M, Chapman MJ. Anticoagulant activity of tissue factor pathway inhibitor in human plasma is preferentially associated with dense subspecies of LDL and HDL and with Lp(a). Arterioscler Thromb. 1993;13:1066-1075.
13. Sandset PM, Lund H, Norseth J, Abildgaard U, Ose L. Treatment with hydroxymethylglutarylcoenzyme A reductase inhibitors in hypercholesterolemia induces changes in components of the extrinsic coagulation system. Arterioscler Thromb. 1991;11:138-145.
14. Bara L, Zitoun D, Bloch MF, Basdevant A, Samama M. Study of coagulation fibrinolysis balance in human hyperlipidemia=contribution of factor VIIa in extrinsic hypercoagulability. XIIth International Congress on Fibrinolysis, Leuven, Belgium, September 18, 1994. Fibrinolysis. 1994;8(suppl):I-14. Abstract 39.
15. Kario K, Miyata T, Sakata T, Matsuo T, Kalo H. Fluorogenic assay of activated factor VII plasma factor VIIa levels in relation to arterial cardiovascular diseases in Japanese. Arterioscler Thromb. 1994;14:265-274.
16. Moor E, Hamsten A, Karpe F, Bavenholm P, Blombäck M, Silveira A. Relationship of tissue factor pathway inhibitor activity to plasma lipoproteins and myocardial infarction at a young age. Thromb Haemost. 1994;71:707-712.
17. Thompson WD, Smith EB. Atherosclerosis and the coagulation system. J Pathol. 1989;159:97-106.
18. Metha J, Metha P, Lawson D, Saldeen T. Plasma tissue plasminogen activator inhibitor levels in coronary artery disease: correlation with age and serum triglyceride concentration. J Am Coll Cardiol. 1987;9:263-268.
19. McLean JW, Tomlinson JE, Kuang WJ, Eaton DL, Chen EY, Fless GM, Scanu AM, Lawn RM. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature. 1987;330:132-137.
20. Edelberg JM, Pizzo SV. Lipoprotein (a): the link between impaired fibrinolysis and atherosclerosis. Fibrinolysis. 1991;5:135-143.
21. Miles PA, Plow EF. An interloper into the fibrinolysis system. Thromb Haemost. 1990;63:331-335.
22. Juhan-Vague I, Alessi MC. Plasminogen activator inhibitor 1 and atherothrombosis. Thromb Haemost. 1993;70:138-143.
23. Schneiderman J, Sawdey MS, Keeton MR, Bordin GM, Bernstein EF, Dilley RB, Loskutoff DJ. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Natl Acad Sci USA. 1992;89:6998-7002.
24. Rath M, Niendorf A, Reblin T, Dietel M, Krebber HJ, Beisiegel U. Detection and quantification of lipoprotein(a) in the arterial wall of 107 coronary bypass patients. Arteriosclerosis. 1989;9:579-592.
25. Cushing GL, Gaubatz JW, Nava ML, Burdick BJ, Bocan TMA, Guyton JR, Weilbaecher D, DeBakey ME, Lawrie GM, Morrisett JD. Quantitation and localization of apolipoproteins [a] and B in coronary artery bypass vein grafts resected at re-operation. Arteriosclerosis. 1989;9:593-603.
26. Prins MH, Hirsh J. A critical review of the relationship between impaired fibrinolysis and myocardial infarction. Am Heart J. 1991;122:545-551.
27. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
28. Wildgoose P, Nemerson Y, Hansen LL, Nielsen FE, Glazer S, Hedner U. Measurement of basal levels of factor Vila in hemophilia A and B patients. Blood, 1992;80:25-28.
29. Hubbard AR, Barrowcliffe TW. Measurement of activated factor VII using soluble mutant tissue factor - proposal for standardization. Thromb Haemost. 1994;72-4:649-650. Letter.
30. Zitoun D, Bara L, Samama MM. Compared activity of human, rat and rabbit plasma tissue factor pathway inhibitor. Thromb Res. 1993;72:269-274.
31. SAS (Statistical Analysis System) procedure. Cary, NC: SAS Institute Inc; 1993.
32. Dejager S, Bruckert E, Chapman MJ. Dense low-density lipoprotein subspecies with diminished oxidative resistance predominate in combined hyperlipidemia. J Lipid Res. 1993;34:295-308.
33. Tornvall P, Karpe F, Carlson LA, Hamsten A. Relationships of low density lipoprotein subfractions to angiographically defined coronary artery disease in young survivors of myocardial infarction. Atherosclerosis. 1991;90:67-80.
34. Hansen J-B, Huseby N-E, Sandset PM, Svensson B, Lyngmo V, Nordøy A. Tissue-factor pathway inhibitor and lipoproteins: evidence for association with and regulation by LDL in human plasma. Arterioscler Thromb. 1994;14:223-229.
35. Stiko-Rahm A, Wiman B, Hamsten A, Nilsson J. Secretion of plasminogen activator inhibitor-1 from cultured human umbilical vein endothelial cells is induced by very low density lipoprotein. Arteriosclerosis. 1990;10:1067-1073.
36. Juhan-Vague I, Alessi MC, Joly P, Thirion X, Vague P, DeClerck PJ, Seradimigni A, Collen D. Plasma plasminogen activator inhibitor-1 in angina pectoris: influence of plasma insulin and acutephase response. Arteriosclerosis. 1989;9:362-367.
37. Koosistra T, Bosma PH, Töns HAM, Van Den Berg AP, Meyer P. Princen HMG. Plasminogen activator inhibitor 1: biosynthesis and mRNA level are increased by insulin in cultured human hepatocytes. Thromb Haemost. 1989;62:723-728.